Rare head and neck tumors, including sarcomas, sarcomatoid squamous cell carcinomas, basaloid squamous cell carcinomas, malignant skin tumors of the external auditory canal, mucosal malignant melanomas, paragangliomas and salivary gland carcinomas, as well as head and neck tumors discussed in the molecular tumor board.
Conditions
Interventions
Group 1: Patients with a histologically confirmed rare head and neck tumor (including sarcomas, sarcomatoid squamous cell carcinomas, basaloid squamous cell carcinomas, malignant skin tumors of the ex
Sponsors
Universitätsklinikum Freiburg
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Histologically confirmed rare head and neck tumor (e.g. sarcoma, sarcomatoid squamous cell carcinoma, basaloid squamous cell carcinoma, malignant skin tumor of the external auditory canal, mucosal malignant melanoma, paraganglioma, salivary gland carcinoma) or presentation of a head and neck tumor at the molecular tumor board - First diagnosis and/or treatment at the Medical Center – University of Freiburg from 01 January 2007 onwards - Adequate documentation of baseline parameters (at least date of diagnosis, tumor site, histological diagnosis, and TNM stage or comparable staging)
Exclusion criteria
Exclusion criteria: - Absence of essential baseline data (e.g. no confirmed histological diagnosis or no information on tumor site) - Objection by the patient to the use of their health data for research purposes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the study is to retrospectively characterize the diagnosis, treatment and clinical outcome of patients with rare head and neck tumors at the Medical Center – University of Freiburg, and to identify factors (clinical, histopathological and radiologic features) associated with a favorable or unfavorable clinical course. From this, prognostic criteria and indicators for the early detection and differentiation of these tumors are to be derived, in order to improve diagnosis, treatment and aftercare in the future. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, progression-free survival and recurrence-free survival (Kaplan-Meier and log-rank analyses, possibly multivariable Cox regression); occurrence of lymph node and distant metastases; resection status; peri- and postoperative complications and revision surgery; in cases with flap reconstruction, graft survival and flap-specific complications; speech, swallowing and voice function; histopathological characteristics (e.g. degree of differentiation, lymphatic, vascular and perineural invasion, resection margins); imaging findings on local and regional tumor extent; association of risk factors (e.g. smoking, alcohol) with clinical outcome. All secondary endpoints are assessed retrospectively over the observation period and analyzed in an exploratory, descriptive manner. | — |
Countries
Germany
Contacts
Public ContactAndreas Spörlein
Universitätsklinikum Freiburg
Outcome results
None listed